SCHEMBL2890963

SCHEMBL2890963

CC(=O)Nc1ccc(C(=O)c2ccc(NC(C)=O)c(C(=O)O)c2)cc1C(=O)O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.65
HSD17B10 Q99714 1/20 0.65
AKR1C3 P42330 10/20 0.53
AKR1C2 P52895 10/20 0.53
TDP1 Q9NUW8 3/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
POLB P06746 1/20 0.51
ALDH1A1 P00352 4/20 0.50
MAPT P10636 3/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
HTT P42858 2/20 0.50
SERPINE1 P05121 1/20 0.50
NEU3 Q9UQ49 1/20 0.49
LMNA P02545 1/20 0.48
RAB9A P51151 1/20 0.48
CYP2C9 P11712 1/20 0.47
HPGD P15428 1/20 0.47
CYP2C19 P33261 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11423645 0.87 POLB (0.54) KDM4EHSD17B10AKR1C3AKR1C2TDP1
SCHEMBL14434162 0.85 ALDH1A1 (0.60) TDP1L3MBTL1POLBALDH1A1MAPT
SCHEMBL7012306 0.82 NEU3 (0.56) KDM4EHSD17B10AKR1C3AKR1C2POLB
SCHEMBL8533041 0.81 KDM4E (0.69) KDM4EHSD17B10TDP1POLBALDH1A1
SCHEMBL31451940 0.81 KDM4E (0.69) KDM4EHSD17B10TDP1POLBALDH1A1
SCHEMBL8962183 0.81 CDC25B (0.66) KDM4EHSD17B10AKR1C3AKR1C2TDP1
SCHEMBL11803827 0.80 KDM4E (0.67) KDM4EHSD17B10AKR1C3AKR1C2L3MBTL1
SCHEMBL7001348 0.80 KDM4E (0.67) KDM4EHSD17B10AKR1C3AKR1C2TDP1
SCHEMBL111313 0.79 ALDH1A1 (0.76) KDM4EHSD17B10AKR1C3AKR1C2TDP1
SCHEMBL5098575 0.79 KDM4E (0.65) KDM4EHSD17B10TDP1POLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110294853-A1 Bis Aromatic Compounds for Use in the Treatment of Inflammation BIOLIPOX AB (SE) 2011-12-01 US disclosed
US-20100286215-A1 BIS-AROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION BIS-AROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION 2010-11-11 US disclosed
EP-2185504-A2 BIS-AROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION Biolipox AB (SE) 2010-05-19 EP disclosed
WO-2010029300-A1 BIS AROMATIC COMPOUNDS FOR USE IN THE TREATMENT OF INFLAMMATION BIOLIPOX AB (SE) 2010-03-18 WO disclosed
WO-2009030887-A2 BIS-AROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION BIOLIPOX AB (SE) 2009-03-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294853-A1 Bis Aromatic Compounds for Use in the Treatment of Inflammation LTC4S, LTB4R2, LTB4R KDM4E 3299/4885HSD17B10 941/4885AKR1C3 74/4885
US-20100286215-A1 BIS-AROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION LTC4S, LTB4R2, LTB4R KDM4E 3526/4885HSD17B10 1159/4885AKR1C3 58/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.